Haemonetics shareholders elect directors, approve executive pay and auditor at 2024 annual meeting

HAEMONETICS CORP

All 9 director nominees elected with ~47.1M–47.6M votes each; no director received less than 46.8M for.
Advisory vote on executive compensation passed with 46.2M for, 1.46M against, 142k abstain.
Ratification of Ernst & Young as auditor for FY ending March 29, 2025: 47.74M for, 1.05M against.
Quorum of 48.9M shares (95.99% of outstanding) present at the July 25, 2024 meeting.
Amendment corrects clerical error in original 8-K regarding fiscal year reference in proposal 3 description.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.